Abstract:Glycogen Synthase Kinase 3 (GSK-3) is a member of cellular kinase with various functions, such as glucose regulation, cellular differentiation, neuronal function and cell apoptosis. It has been proved as an important therapeutic target in type 2 diabetes mellitus and Alzheimer's disease. To better understand their structure–activity relationships and mechanism of action, an integrated computational study, including three dimensional quantitative structure-activity relationship (3D-QSAR), molecular docking, and molecular dynamics (MD), was performed on 79 (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine GSK-3 inhibitors. In this paper, we constructed 3D-QSAR using comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) method. The results showed that the CoMFA model (q 2 = 0.743, r2 = 0.980) and the CoMSIA model (q2 = 0.813, r2 = 0.976) had stable and reliable predictive ability. The electrostatic and H-bond donor fields play important roles in the models. The contour maps of the model visually showed the relationship between the activity of compounds and their three-dimensional structure. Molecular docking was used to identify the key amino acid residues at the active site of GSK-3 and explore its binding mode with ligands. Based on 3D-QSAR models, contour maps and the binding feature between GSK-3 and inhibitor, we designed 10 novel compounds with good potential activity and ADME/T profile. Molecular dynamics simulation results validated that Ile62, Val70 and Lys85 located in the active site play a key role for GSK-3 complexed with inhibitors. These results might provide important information for designing GSK-3 inhibitors with high activity.

ChemInform Abstract: Design, Synthesis and Biological Evaluation of Benzothiazepinones (btzs) As Novel Non‐ATP Competitive Inhibitors of Glycogen Synthase Kinase‐3β (Gsk‐3β).

Design, Synthesis and Biological Evaluation of Benzothiazepinones (btzs) As Novel Non-Atp Competitive Inhibitors of Glycogen Synthase Kinase-3Β (Gsk-3Β).

Design,synthesis and biological evaluation of benzothiazinones as novel non-ATP competitive inhibitors of glycogen synthesis kinase 3β(GSK-3β)

Discovery and Anti-Inflammatory Evaluation of Benzothiazepinones (btzs) As Novel Non-Atp Competitive Inhibitors of Glycogen Synthase Kinase-3Β (Gsk-3Β).

Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.

Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3β (GSK-3β) inhibitors

Design, Synthesis and in Vitro Test of Novel Non-ATP Competitive Glycogen Synthase Kinase-3β(GSK-3β)Inhibitors

Design, Synthesis and Evaluation of 7-Azaindazolyl-indolyl-maleimides As Glycogen Synthase Kinase-3Β (Gsk-3Β) Inhibitors

Identification of Novel Scaffold of Benzothiazepinones As Non-Atp Competitive Glycogen Synthase Kinase-3Β Inhibitors Through Virtual Screening.

ChemInform Abstract: Design, Synthesis, and Evaluation of 3-Aryl-4-pyrrolylmaleimides as Glycogen Synthase Kinase-3β Inhibitors.

Design, Synthesis, and Evaluation of 3‐aryl‐4‐pyrrolyl‐maleimides As Glycogen Synthase Kinase‐3β Inhibitors

Design, synthesis and biological evaluation of thieno[3,2- c ]pyrazol-urea derivatives as potent glycogen synthase kinase 3β inhibitors based on the DFG-out conformation

Design, Synthesis and Evaluation of 3-(2-aminoheterocycle)-4-benzyloxyphenylbenzamide Derivatives As BACE-1 Inhibitors

Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3 Inhibitors for the Treatment of Acute Promyelocytic Leukemia

Design and Synthesis of (aza)indolyl Maleimide-Based Covalent Inhibitors of Glycogen Synthase Kinase 3Β.

Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.

In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation

Benzo[E]Isoindole-1,3-Diones As Potential Inhibitors of Glycogen Synthase Kinase-3 (Gsk-3). Synthesis, Kinase Inhibitory Activity, Zebrafish Phenotype, and Modeling of Binding Mode

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia